Survival Improvements in Advanced Hepatocellular Carcinoma with Sequential Therapy by Era
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Survival Improvements in Advanced Hepatocellular Carcinoma with Sequential Therapy by Era
Authors
Keywords
-
Journal
Cancers
Volume 15, Issue 21, Pages 5298
Publisher
MDPI AG
Online
2023-11-06
DOI
10.3390/cancers15215298
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)
- (2023) Kiyoshi Hasegawa et al. HEPATOLOGY RESEARCH
- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
- (2022) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma
- (2022) Masatoshi Kudo International Journal of Clinical Oncology
- Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL)
- (2022) Kazuya Okushin et al. JOURNAL OF GASTROENTEROLOGY
- Does first‐line treatment have prognostic impact for unresectable HCC ?—Atezolizumab plus bevacizumab versus lenvatinib
- (2022) Atsushi Hiraoka et al. Cancer Medicine
- Global burden of primary liver cancer in 2020 and predictions to 2040
- (2022) Harriet Rumgay et al. JOURNAL OF HEPATOLOGY
- Hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Disease Primers
- A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration
- (2021) Qian He et al. Therapeutic Innovation & Regulatory Science
- Disease Burden, Risk Factors, and Recent Trends of Liver Cancer: A Global Country-Level Analysis
- (2021) Junjie Huang et al. Liver Cancer
- Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
- (2021) Masatoshi Kudo et al. Liver Cancer
- Report of the 22nd Nationwide Follow‐Up Survey of Primary Liver Cancer in Japan (2012–2013)
- (2021) Masatoshi Kudo et al. HEPATOLOGY RESEARCH
- Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
- (2021) Yuka Hayakawa et al. INVESTIGATIONAL NEW DRUGS
- Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma
- (2021) Kazufumi Kobayashi et al. Liver Cancer
- Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990‐2017
- (2020) Zhenqiu Liu et al. CANCER
- Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference
- (2020) Josep M. Llovet et al. HEPATOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
- (2020) Masatoshi Kudo et al. Liver Cancer
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015
- (2018) Nathan G. Kim et al. CANCER
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis.
- (2018) Markus Peck-Radosavljevic et al. JOURNAL OF CLINICAL ONCOLOGY
- A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update
- (2018) Ryosuke Tateishi et al. JOURNAL OF GASTROENTEROLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version
- (2011) Masatoshi Kudo et al. DIGESTIVE DISEASES
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started